Inhibikase Therapeutics (NYSE:IKT) Earns “Neutral” Rating from HC Wainwright

Inhibikase Therapeutics (NYSE:IKT)‘s stock had its “neutral” rating reissued by HC Wainwright in a note issued to investors on Friday,Benzinga reports.

Inhibikase Therapeutics Trading Down 7.4 %

Shares of NYSE:IKT traded down $0.18 during trading on Friday, hitting $2.20. 40,320 shares of the company’s stock traded hands, compared to its average volume of 171,426. The company has a 50-day moving average price of $2.43 and a 200-day moving average price of $2.38. Inhibikase Therapeutics has a 52 week low of $1.12 and a 52 week high of $4.20. The company has a market cap of $152.25 million, a price-to-earnings ratio of -0.82 and a beta of 1.04.

Hedge Funds Weigh In On Inhibikase Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Stifel Financial Corp acquired a new stake in shares of Inhibikase Therapeutics in the 4th quarter valued at about $43,000. Jefferies Financial Group Inc. bought a new position in shares of Inhibikase Therapeutics during the fourth quarter worth about $48,000. Alpine Global Management LLC acquired a new stake in Inhibikase Therapeutics in the 4th quarter valued at approximately $48,000. Caxton Corp acquired a new stake in Inhibikase Therapeutics in the 4th quarter valued at approximately $53,000. Finally, Squarepoint Ops LLC bought a new stake in Inhibikase Therapeutics in the 4th quarter valued at approximately $92,000. 3.81% of the stock is owned by institutional investors and hedge funds.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.